ニュース提供 KeyBioscience AG 10 10月, 2024, 23:00 JSTこの記事をシェアする 両社はDACRAに関する共同試験を延長し、共同試験分子を追加するとともに、複数の適応症におけるDACRAプラットフォームの調査を実施 スイス、ルガーノ, 2024年10月10日 /PRNewswire/ -- KeyBioscienceとEli Lilly...
Learn more Contact us How can we help you? Are you interested in learning more about KeyBioscience? Get in touch KeyBioscience AG Via Francesco Soave 6 – 6900 Lugano tel. +41 79 520 70 86
LUGANO, Switzerland - KeyBiosiscience AG, a subsidiary of Nordic Bioscience Holding A/S and an affiliate of Nordic Bioscience A/S, and Eli Lilly and Company have agreed to extend their collaboration on the development of Dual...
瑞士卢加诺2024年10月10日/美通社/ -- KeyBioscience和Eli Lilly and Company(礼来公司)已同意扩展其在开发双淀粉降钙素受体激动剂(DACRA)上的合作,DACRA是一种针对肥胖症及其相关疾病的新型潜在治疗药物。 此次合作扩大了Lilly对KeyBioscience DACRA平台的权利,包括一种新分子,预计将在今年晚些时候进入肥胖和骨关节...
这不2017年6月8日,礼来官网宣布与 KeyBioscience AG 达成新的合作协议开发新型双糊精及降钙素受体激动剂Dual Amylin Calcitonin Receptor Agonists (DACRAs)治疗代谢性疾病,比如2型糖尿病,该类药物可以提高胰岛素敏感性并促进糖尿病患者的体重减轻。合作包括使用后者DACRA平台包括多个化合物 KBP-042, KBP-089和KBP-05...
The inherent heterogeneity of tumor cells impedes the development of targeted therapies for specific glioblastoma (GBM) subtypes. This study aims to investigate the mesenchymal subtype of GBM to uncover detailed characteristics, potential therapeutic str
Within the field of terahertz science and technology, one of the most active areas of current research focuses on the intersection of terahertz measurements and methods with the world of biology and medicine. Current activities revolve around numerous diverse questions, ranging from studies of the ...